Summary

How Schwarz Pharma, Inc. maps according to Revere

Sector Level Count
Industries 1
Sectors 2
Subsectors 10
Product/Service Groups 37

Specific product example for Schwarz Pharma, Inc.

Product Hierarchy
Healthcare
Biopharmaceuticals
Cardiovascular System
Heart Disorders
Angina
Vasodilatory Agents

Company Highlights:

Market Cap. n/a
Current Shares Outstnd. n/a
Contact Name
Contact Phone  
City, State ,
Dividends Per Common Share n/a
Dividend Yield n/a
SI %SHOUT n/a
IH % Shares Outst. n/a
Number of Employees n/a
Revenue Per Employee n/a
Book Value Per Share n/a
5 Year CAGR in Revenues % n/a
5 Year CAGR in Earnings % n/a
Asset Turnover n/a
Fiscal Year End n/a
Next Reporting Period n/a

Products

Products Manufactured/Services Performed Details
Healthcare
Biopharmaceuticals
Cardiovascular System
Heart Disorders
Angina
Vasodilatory Agents

Products:

  • Monoket (Isosorbide Mononitrate)
  • Dilatrate-SR (Isosorbide Dinitrate)
Vascular Disorders
Hypertension
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)

Products:

  • Univasc (Moexipril Hydrochloride)
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)/Thiazide Diuretic Agents

Products:

  • Uniretic (Moexipril Hydrochloride/Hydrochlorothiazide)
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)

Products:

  • Levatol (Penbutolol Sulfate)
Calcium Channel Blocking Agents

Products:

  • Verelan/Verelan PM (Verapamil Hydrochloride)
Dermatology
Lesion/Scaling Disorders
Dermatoses
Steroidal Anti-Inflammatory Drugs (SAID)/Sodium Channel Blocking Agents

Products:

  • Epifoam (Hydrocortisone/Pramoxine)
  • Proctofoam-HC (Hydrocortisone/Pramoxine)
Digestive System
Gastrointestinal Tract Disorders
Gastroduodenal Disorders
Peptic Ulcers
Duodenal
Anticholinergic Agents

Products:

  • Nulev (Hyoscyamine Sulfate)
H2 Receptor Antagonists

Products:

  • Fluxid (Famotidine Orally Disintegrating Tablet)
Gastric
Anticholinergic Agents

Products:

  • Nulev (Hyoscyamine Sulfate)
H2 Receptor Antagonists

Products:

  • Fluxid (Famotidine Orally Disintegrating Tablet)
Zollinger-Ellison Syndrome
H2 Receptor Antagonists

Products:

  • Fluxid (Famotidine Orally Disintegrating Tablet)
Gastroesophageal Disorders
Gastroesophageal Reflux Disease (GERD)
Dopamine Receptor Blocking Agents

Products:

  • Reglan/Reglan ODT (Metoclopramide Hydrochloride)
H2 Receptor Antagonists

Products:

  • Fluxid (Famotidine Orally Disintegrating Tablet)
Gastroparesis
Dopamine Receptor Blocking Agents

Products:

  • Reglan/Reglan ODT (Metoclopramide Hydrochloride)
Nausea/Vomiting
Dopamine Receptor Blocking Agents

Products:

  • Reglan/Reglan ODT (Metoclopramide Hydrochloride)
Intestinal Disorders
Constipation
Chronic
Stool Softeners/Stimulants

Products:

  • Colyte
  • Glycolax (Polyethylene Glycol)
Intestinal Intubation
Dopamine Receptor Blocking Agents

Products:

  • Reglan/Reglan ODT (Metoclopramide Hydrochloride)
Rectal Disorders
Hemorrhoids
Sodium Channel Blocking Agents

Products:

  • Proctofoam Non Steroid (Pramoxine Hydrochloride)
Steroidal Anti-Inflammatory Drugs (SAID)/Sodium Channel Blocking Agents

Products:

  • Proctofoam-HC (Hydrocortisone/Pramoxine)
Proctitis
Steroidal Anti-Inflammatory Drugs (SAID)

Products:

  • Cortifoam (Hydrocortisone)
Musculoskeletal System
Phase I/Phase II Clinical Stage Products

Products:

  • Neupro (Rotigotine Continuous Delivery System Patch)
  • Lacosamide
Neurology
Neuromuscular Disorders
Parkinson`s Disease (PD)
Adjunctive Treatments
Dopamine Receptor Agonists

Products:

  • Parcopa (Carbidopa/Levodopa)
Monotherapy
Dopamine Receptor Agonists

Products:

  • Neupro (Rotigotine Continuous Delivery System Patch)
Restless Leg Syndrome
Dopamine Receptor Agonists

Products:

  • Neupro (Rotigotine Continuous Delivery System Patch)
Phase I/Phase II Clinical Stage Products

Products:

  • Rotigotine Nasal Spray For The Treatment Of Acute Parkinson's Symptoms
Psychiatric Disorders
Anxiety
Generalized Anxiety Disorder (GAD)
Gamma-Aminobutyric Acid (GABA) Receptor Agonists

Products:

  • Niravam (Alprazolam Orally Disintegrating Tablets)
Panic Disorder
Gamma-Aminobutyric Acid (GABA) Receptor Agonists

Products:

  • Niravam (Alprazolam Orally Disintegrating Tablets)
Pain Management
Narcotics
Analgesics/Opioids

Products:

  • Co-Gesic (Hydrocodone Bitartrate/Acetaminophen)
Non-Narcotics
Skeletal Muscle Relaxing Agents

Products:

  • Robaxin (Methocarbamol)
Phase I/Phase II Clinical Stage Products

Products:

  • Lacosamide
Research/Preclinical Stage Products

Products:

  • PAC20030
Respiratory System
Upper Respiratory Tract Disorders
Coughs/Colds
Decongestants/Expectorants

Products:

  • Guaimax-D (Pseudoephedrine HCl/Guaifenesin)
Surgery
Digestive System
Bowel Evacuation
Hyperosmotic Agents

Products:

  • Colyte
Urology
Male Genital Disorders
Penile
Erectile Dysfunction (Impotence)
Vasodilatory Agents

Products:

  • Edex (Alprostadil)
Urological Disorders
Bladder
Neurogenic Bladder Disease
Anticholinergic Agents

Products:

  • Nulev (Hyoscyamine Sulfate)
Urinary Frequency/Urge Incontinence
Muscarinic Receptor Antagonists

Products:

  • Fesoterodine
Nutritional Health
Dietary/Naturopathic Supplements
General Health

Products:

  • Schwartz Pharma

Key Financials

Period Length/End
Total Revenue
Gross Margin %
Operating Income
Operating Margin %
Tax Rate %
Income After Taxes
Net Income Margin %
F.D. EPS - Incl. Xord. Items
Book Value Per Share

Ratios

P/R Ratio (TTM) n/a
P/E Ratio (TTM) n/a
Price To Free Cash Flow (TTM) n/a
Price To Book Value n/a
Net Assets to Market Cap. % n/a
Beta n/a
Days to Sell Inventory n/a
Current Ratio n/a
Quick Ratio n/a
Interest Coverage n/a
Debt to Market Cap. % n/a
Return on Equity % n/a
Return on Assets % n/a
Return on Invested Capital % n/a

Major Competitors

Name Trailing Revenue P/R Ratio (TTM) P/E Ratio (TTM) 1 Year Return % Overlap
Average          

Notes:

Customers

Name Last Quarter Financial Stats 1 YR Price Performance %
Y/Y Revenue Growth % Sequential Revenue Growth % Y/Y Margin Growth % Sequential Margin Growth %
Otsuka Pharmaceutical Co., Ltd. n/a n/a n/a n/a n/a
Pfizer Inc. 2.12 7.34 69.68 335.05 -18.59%
Average 2.12 7.34 69.68 335.05 -18.59%

Notes:

Strategic Partners

Name Subtypes 1 YR Price Performance %
Otsuka Pharmaceutical Co., Ltd. Distribution, Out-licensing, Research Collaboration n/a
Pfizer Inc. Out-licensing -18.59%
UCB S.A. Investors n/a

Business/Geographical Segments